一、审议通过《关于不向下修正"洁特转债"转股价格的议案》 具体内容详见公司同日刊载于《中国证券报》《证券时报》《上海证券报》 《证券日报》及上海证券交易所（www.sse.com.cn）的《关于不向下修正"洁特 转债"转股价格的公告》（公告编号：2025-068）。 表决结果：4 票同意，0 票反对，0 票弃权。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-067 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十五次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十 五次会议于 2025 年 11 月 21 日以通讯的方式召开，会议通知已于 2025 年 11 月 14 日通过电子邮件的方式送达全体董事。本次会议应出席董事 7 人，实际出席 董事 7 人。会议由董事长袁建华主持，会议召开符合有关法律、法规、规章和 ...

Core Insights - The company, Jiet Bio (688026.SH), has reported an overall capacity utilization rate of approximately 60% [1] - A new factory has partially commenced operations, but some equipment and production lines are still in the debugging phase, with full production dependent on order volume [1] - The company's main products include over 80 categories of biological laboratory consumables, such as cell culture and liquid handling products, which have a strong sales market [1]

Core Viewpoint - The company is potentially triggering a downward adjustment of the conversion price for its convertible bonds due to stock prices falling below a specified threshold, which may impact investor decisions and the company's financial strategy [2][8]. Convertible Bond Issuance - The company issued a total of 4.4 million convertible bonds with a face value of 100 RMB each, raising a total of 440 million RMB, with a maturity period from June 28, 2022, to June 27, 2028 [2][3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and will further adjust to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025, due to annual equity distribution plans [3][4]. Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the company's stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5][6]. - The potential trigger for this adjustment is set to begin on November 3, 2025, with a threshold price of 40.76 RMB per share [8]. Adjustment Procedure - If the company decides to adjust the conversion price, it will announce the details, including the adjustment range and the record date for shareholders, through the Shanghai Stock Exchange [7].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-066 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于"洁特转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025 年 11 月 3 日至 2025 年 11 月 14 日，广州洁特生物过滤股份有限公 司股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发转股价格 向下修正条件。若未来触发转股价格向下修正条款，公司董事会将召开会议决定 是否行使"洁特转债"转股价格的向下修正权利，并及时履行信息披露义务。 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 的有关规定，广州洁特生物过滤股份有限公司（以下简称"公司"）可能触发可转 换公司债券（以下简称"可转债"）转股价格向下修正条件的相关情况如下： 一、可转债发行上市情况 经上海证券交易所自律监管决定书（[20 ...

Core Points - Jiet Bio announced that from November 3 to November 14, 2025, its stock has closed below 85% of the current conversion price for 10 trading days, which is expected to trigger the downward adjustment of the conversion price [1] - If the downward adjustment clause for "Jiet Convertible Bonds" is triggered, the company's board will convene to decide whether to exercise the downward adjustment rights and will fulfill its information disclosure obligations in a timely manner [1]

Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is actively involved in legal disputes and has made significant investments in a new industrial fund aimed at enhancing its strategic development and capital cooperation in the biopharmaceutical sector [6][10]. Financial Data - The financial report for the third quarter indicates that the financial statements have not been audited [3][8]. - The company has reported significant legal disputes involving its subsidiaries, which may impact its financial standing [6][7]. Legal Disputes - A subsidiary, Baifeier, has filed a lawsuit against Shanghai Deyou Electronic Technology Co., Ltd. for a contract dispute involving a total amount of approximately 18.44 million yuan, with a breach penalty of 1.39 million yuan [6]. - The court ruled in favor of Baifeier in the first instance, ordering the return of 18.44 million yuan and a penalty of approximately 922,084.59 yuan, but the defendant has appealed [6]. - Another dispute with Shenzhen Hesheng Medical Technology Co., Ltd. involves a claim of approximately 10.34 million yuan, with the court initially ruling in favor of the company, but the case is currently under appeal [7]. Investment Activities - The company has initiated the establishment of an industrial fund, Guangzhou Zengcheng Nante Biopharmaceutical Investment Partnership, with a total investment of 50.01 million yuan, where the company contributes 25 million yuan, representing 49.99% of the total [10][11]. - The fund aims to invest in early to mid-stage biopharmaceutical projects, enhancing the company's strategic development and capital cooperation [10]. Fund Registration - The fund has completed registration with the China Securities Investment Fund Industry Association and has received the private investment fund registration certificate on October 29, 2025 [12].

Core Viewpoint - Jiet Bio, established in 2001 and listed in 2020, specializes in disposable plastic consumables for biological laboratories, with a strong technical foundation and products exported to over 70 countries [1] Group 1: Business Performance - In Q3 2025, Jiet Bio reported revenue of 398 million yuan, ranking 35th among 50 companies in the industry, significantly lower than the top competitors, with the industry average at 137.9 million yuan [2] - The main business segments include liquid handling (337 million yuan, 60.24%), cell culture (172 million yuan, 30.74%), and others (27.83 million yuan, 4.98%) [2] - The net profit for the same period was 58.63 million yuan, ranking 32nd in the industry, again trailing behind leading companies [2] Group 2: Financial Ratios - As of Q3 2025, Jiet Bio's debt-to-asset ratio was 28.75%, higher than the industry average of 23.66%, indicating some pressure on debt repayment capacity [3] - The gross profit margin was 42.17%, an increase from the previous year but still below the industry average of 48.78%, suggesting room for improvement in profitability [3] Group 3: Management and Shareholder Structure - The chairman, Yuan Jianhua, saw a salary reduction from 1.2 million yuan in 2023 to 1.07 million yuan in 2024, while the general manager's salary increased from 1.80 million yuan to 2.0165 million yuan [4] - As of September 30, 2025, the number of A-share shareholders increased by 5.43% to 8,274, with an average holding of 17,000 circulating A-shares, a decrease of 5.12% [5] Group 4: Market Outlook and Growth Projections - Jiet Bio is focusing on expanding its market presence, with a projected revenue growth to 652 million yuan in 2025, 772 million yuan in 2026, and 919 million yuan in 2027, alongside net profits of 98 million yuan, 118 million yuan, and 145 million yuan respectively [5][6] - The company is enhancing its product offerings and pursuing cost reductions through high-end product development and smart manufacturing [5]

Core Viewpoint - Jiet Bio (688026.SH) reported its Q3 2025 results, showing modest growth in revenue and significant increases in net profit and earnings per share [1] Financial Performance - The company achieved a revenue of 398 million yuan for the first three quarters, representing a year-on-year growth of 1.88% [1] - The net profit attributable to shareholders reached 57.29 million yuan, marking a year-on-year increase of 14.22% [1] - The non-recurring net profit was 53.16 million yuan, reflecting a year-on-year growth of 20.71% [1] - Basic earnings per share stood at 0.42 yuan [1]

Core Insights - The company reported a revenue of 398,180,432.24 yuan for the first three quarters of 2025, representing a year-on-year growth of 1.88% [1] - The net profit attributable to shareholders of the listed company was 57,291,336.80 yuan, showing a year-on-year increase of 14.22% [1] Financial Performance - Revenue for the first three quarters of 2025: 398.18 million yuan, up 1.88% year-on-year [1] - Net profit for the same period: 57.29 million yuan, up 14.22% year-on-year [1]